Fortis Healthcare Ltd has approved the reappointment of Ashutosh Raghuvanshi as Managing Director for a further period of two years effective from March 19, 2027. According to the company's regulatory filing, the current term of Raghuvanshi as Managing Director (designated as Managing Director and Chief Executive Officer) is expiring on March 18, 2027. The reappointment was approved during the board meeting held on July 8, 2026, and is subject to approval of the shareholders, as reported by Angel One.
The board of directors recommended Raghuvanshi's re-appointment based on his expertise and role in steering the growth of the company. As reported by Angel One, the board made this decision during their meeting held on July 8, 2026, underscoring their confidence in Raghuvanshi's leadership capabilities and his contribution to the company's growth trajectory. The decision reflects the board's recognition of his extensive experience and pivotal role in Fortis Healthcare's development.
Dr. Ashutosh Raghuvanshi, aged 64, brings over 38 years of experience in the healthcare sector to his leadership role. According to Angel One, he holds an MBBS and M.S. in General Surgery from Mahatma Gandhi Institute of Medical Sciences, Wardha, and an M.Ch. in Cardiac Surgery from Bombay Hospital Institute of Medical Sciences. Prior to joining Fortis, Raghuvanshi served in various leadership roles at Narayana Health, a prominent healthcare chain, demonstrating his proven track record in the industry.
Fortis Healthcare share price was trading at ₹941.75 on NSE as of July 8, 2026, at 3:30 PM, representing a 3.10% decline from the previous closing price. As per Angel One, the market reaction reflects investor sentiment following the leadership continuity announcement. The share price movement occurred alongside the board's decision to extend Raghuvanshi's tenure, indicating market expectations around the company's leadership stability.
